PREVENTION OF MORTALITY WITH LONG-TERM ADMINISTRATION OF HUMAN ALBUMIN IN SUBJECTS WITH DECOMPENSATED CIRRHOSIS AND ASCITES

Registry ID

IG1601

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

INSTITUTO GRIFOLS S.A.

Last update

2021-04-13

Conditions

• CIRRHOSIS OF THE LIVER

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFECT OF SELADELPAR ON CLINICAL OUTCOMES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND COMPENSATED CIRRHOSIS
• A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
• EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER DISEASE
• A PHASE III RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR 80 MG ON LONG-TERM CLINICAL OUTCOMES IN ADULT PARTICIPANTS WITH PRIMARY BILIARY CHOLANGITIS (PBC)
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AXA1665 IN SUBJECTS WITH LIVER CIRRHOSIS AND PRIOR OVERT HEPATIC ENCEPHALOPATHY (EMMPOWER)
• A SEAMLESS, ADAPTIVE, PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, INTERNATIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BELAPECTIN (GR-MD-O2) FOR THE PREVENTION OF ESOPHOGEAL VARICES IN NASH CIRRHOSIS

View on source registry